Pharmala Biotech Holdings Performance
| PMBHFDelisted Stock | 0.25 0.00 0.00% |
The company holds a Beta of -1.78, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Pharmala Biotech are expected to decrease by larger amounts. On the other hand, during market turmoil, Pharmala Biotech is expected to outperform it. Pharmala Biotech Holdings right now holds a risk of 0.0%. Please check Pharmala Biotech Holdings downside deviation, treynor ratio, expected short fall, as well as the relationship between the jensen alpha and potential upside , to decide if Pharmala Biotech Holdings will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Pharmala Biotech Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable technical indicators, Pharmala Biotech is not utilizing all of its potentials. The latest stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
Pharmala |
Pharmala Biotech Relative Risk vs. Return Landscape
If you would invest 25.00 in Pharmala Biotech Holdings on September 16, 2024 and sell it today you would earn a total of 0.00 from holding Pharmala Biotech Holdings or generate 0.0% return on investment over 90 days. Pharmala Biotech Holdings is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Pharmala, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Pharmala Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pharmala Biotech's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Pharmala Biotech Holdings, and traders can use it to determine the average amount a Pharmala Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| PMBHF |
Based on monthly moving average Pharmala Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pharmala Biotech by adding Pharmala Biotech to a well-diversified portfolio.
Things to note about Pharmala Biotech Holdings performance evaluation
Checking the ongoing alerts about Pharmala Biotech for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Pharmala Biotech Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pharmala Biotech is not yet fully synchronised with the market data | |
| Pharmala Biotech has some characteristics of a very speculative penny stock |
- Analyzing Pharmala Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pharmala Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Pharmala Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pharmala Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pharmala Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pharmala Biotech's pink sheet. These opinions can provide insight into Pharmala Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Pharmala Pink Sheet
If you are still planning to invest in Pharmala Biotech Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pharmala Biotech's history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |